Glasdegib (PF-04449913)

Cat. No.: OB0225WX-2670

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Glasdegib is an orally bioavailable small molecule that acts as a potent inhibitor of the Smoothened (Smo) receptor with an IC50 of 5 nM.

Synonym: Glasdegib; 1095173-27-5; PF-04449913; PF 04449913; 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea; glasdegibum; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea; Glasdegib (PF-04449913); PF-4449913; PF-913; 1-((2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea; N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-N'-(4-cyanophenyl)urea; Urea, N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)-; N-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)-urea, ; PF 04449913; MFCD25976839

CAS No.: 1095173-27-5

Compound CID: 25166913

Formula: C₂₁H₂₂N₆

Formula Weight: 374.44

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Glasdegib is used in stem cell and oncology research as an orally active Smoothened (Smo) inhibitor to investigate the regulation of the Hedgehog signaling pathway in myeloid malignancies.